AstraZeneca's camizestrant ambitions stumble as FDA panel rejects novel oral SERD proposal

An FDA expert panel on Thursday voted 6 to 3 against AstraZeneca's proposal of using its oral SERD camizestrant in a novel first-line switch setting in HR-positive, HER2-negative metastatic breast cancer, dealing an early blow to the British pharma's $5 billion peak sales plan.

By FierceBiotech · May 2, 2026 · via FierceBiotech

AstraZeneca's camizestrant ambitions stumble as FDA panel rejects novel oral SERD proposal

Image: FierceBiotech

This is an aggregated industry headline. Read the full story at FierceBiotech →

RxInsider combines reported facts with industry analysis and informed inference. Forward-looking reads, market commentary, and interpretive framing reflect analysis of available reporting and known facts, not confirmed outcomes.